Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Understanding zero based budgeting versus traditional budgeting can enhance your financial strategy. Explore the key differences today.
19,444 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Arm is venturing into silicon design after decades as a licensing powerhouse. This bold shift could impact AI data ce...
Nvidia’s valuation move is drawing attention from investors weighing AI demand against broader market momentum. This ...
For investors who can stomach big swings, choosing between XRP and Hyperliquid isn’t simple. This guide breaks down r...
Political rhetoric can shake markets and impact wallets. This article breaks down how trump’s “election integrity arm...
AI-driven threats are accelerating demand for security software, and a trio of under-$30 cyber names could offer mean...
Markets cooled early May 2026 as inflation data rolled in, but investors pressed ahead with digital planning. This re...
A wave of upgrades is reshaping Near Protocol. Privacy features, AI-ready smart contracts, and scaling improvements c...
KPMG is embedding Claude into its Digital Gateway to address two AI fears and a market shift, aiming to redefine how ...
Gossamer Bio's 2026 earnings outlook centers on cash runway, pipeline progress, and strategic partnerships. This arti...
As the clean energy shift accelerates, two hydrogen-focused leaders—Bloom Energy and Plug Power—offer distinct paths ...
When a century-spanning blue-chip changes its share count, investors take notice. This article breaks down what a rev...